KinCon biolabs GmbH is among the five innovative companies selected for funding from the recent 2.4 million Euro call for research and development projects by Health Hub Tirol. This initiative, launched last November, aims to propel advancements in the fields of life sciences, medical technology, e-health, pharmaceuticals, and biotechnology.
Health Hub Tirol, spearheaded by the state of Tyrol, is dedicated to fostering innovation and enhancing Tyrol's reputation as a global health region. It offers crucial infrastructure, industry-specific services for life sciences companies, access to funding opportunities, and additional capital.
For KinCon biolabs, this funding will significantly advance its mission to accelerate the development of personalized medicines. Utilizing their unique molecular reporters, KinCon aims to make substantial strides in drug discovery, particularly focusing on Parkinson's disease. The financial support from Health Hub Tirol will enable the company to expand its research capabilities, develop innovative solutions, and bring them closer to market, ultimately improving patient outcomes and reinforcing Tyrol's standing in the global health sector.
